Skip to main content

IM011023 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease

NCT03599622

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Bristol-Myers Squibb Company

The purpose of this research study is to measure how effective and how safe BMS-9986164 is in treating study participants with moderate to severe Crohn's Disease (CD). The assessment will be done by measurements on how you are feeling, any side effects or changes to your laboratory tests.

This study is currently enrolling.